Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357040 · ClinicalTrials.gov registry record · Phase 2
Antidepressant Effects of Nitrous Oxide
A Phase 2 study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 2
- Study locations
NCT05357040 is a Phase 2 study of Major Depressive Disorder and Treatment-Resistant Depression that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 172 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (54% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05357040, a Phase 2 study of Major Depressive Disorder and Treatment-Resistant Depression, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nitrous oxide gas for inhalation
Study Locations (2)
Illinois
- University of Chicago Medicine - Chicago
Victoria
- The Alfred Hospital - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05357040
The ClinicalTrials.gov registry entry for NCT05357040 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (54% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05357040 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Victoria.
Frequently Asked Questions
What is clinical trial NCT05357040 about?
NCT05357040 is a clinical study titled "Antidepressant Effects of Nitrous Oxide". To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.
What is the current status of trial NCT05357040?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2021-06-30. Estimated completion is 2026-12-01.
What conditions does trial NCT05357040 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Treatment-Resistant Depression.
What interventions are being tested in trial NCT05357040?
The interventions under investigation include: Placebo (DRUG), Nitrous oxide gas for inhalation (DRUG).
Who is sponsoring clinical trial NCT05357040?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357040 being conducted?
This trial has 2 study locations across Illinois, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.